Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology.

Umut Demırcı ,Mustafa Benekli,Umut Kefeli,Hilmi Kodaz,Murat Akyol,Burcu Yapar Taşköylü ,Çağlayan Geredeli ,Aydın Çiltaş ,Şener Cihan ,Aziz Karaoğlu ,Bayram Öztürk ,Mehmet Şeker ,Utku Oflazoğlu ,Muhammed Bülent Akıncı ,O Yazıcı ,Alper Sevinç ,Mükremın Uysal ,Ayşe Ocak Duran ,Didem Taştekin ,Suleyman Büyükberber

doi:10.1200/jco.2014.32.15_suppl.e16094

Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (MCRPC) after docetaxel chemotherapy: Multicentric experience of Anatolian Society of Medical Oncology.

Umut Demırcı , Mustafa Benekli + Show 18 more

https://doi.org/10.1200/jco.2014.32.15_suppl.e16094

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2014
Citations: 2

Affiliation: Gazi University, Trakya University, Izmir Kâtip Çelebi University, Pamukkale University, Konya Numune Hastanesi, Okmeydanı Eğitim ve Araştırma Hastanesi, Dokuz Eylül University, Gaziosmanpaşa University, Sivas Cumhuriyet Üniversitesi, Ankara Atatürk Eğitim ve Araştırma Hastanesi, Ministry of Health, Gaziantep University, Afyon Kocatepe University, Erciyes University, Istanbul University

#Metastatic Castration-resistant Prostate Cancer #Safety Of Abiraterone Acetate + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

e16094 Background: We evaluated the efficiency and safety of AA in patients with MCRPC after docetaxel chemotherapy. Methods: Between April 2011 and January 2014, we retrospectively evaluated survi...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.